Meda buys Italian company for more than EUR 2bn
After having rejected a number of approaches from generics giant Mylan, Sweden’s Meda has forked over EUR 2.275 billion for an Italian drug group.
BY BENJAMIN WERNER CHRISTENSEN
In the beginning of July, Italian pharmaceutical company Rottapharm pulled out of a planned IPO – and new light has been shed on the reasons for that move. The Swedish drug group Meda announced last week that it has agreed to buy Rottapharm for EUR 2.275 billion, which includes debt of EUR 300 million, meaning Meda is paying a cash price of EUR 1.975 billion, the Swedish company writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
